Re2O Cannula vs Dermashine: What Does the Clinical Evidence Actually Show?
Re2O Cannula vs Dermashine: What Does the Clinical Evidence Actually Show?
The key question is not simply which tool is used, but where, at what depth, and with what spatial distribution the product is delivered.
Written by M.D. Bo Won Lee, Director of Springday Clinic Sinchon, Seoul.
The published 2026 Re2O clinical study used an automated Dermashine injector targeting the mid-dermis.
The study did not compare Dermashine directly with cannula injection.
Technique should be selected according to treatment area, tissue plane, anatomy, and the desired distribution.
The question I hear most often
Patients researching Re2O often encounter conflicting statements online. Some are told that the product should be delivered with a cannula, while others see clinics using automated multineedle injectors or manual needle techniques.
The first point to understand is that a cannula and a needle do not place material into tissue in the same spatial pattern.
This does not make one universally superior. It means that the appropriate tool depends on what the physician is trying to accomplish.
Cannula delivery and point-by-point injection solve different problems
A blunt cannula is typically introduced through an entry point and advanced along a tissue plane. Product may then be deposited using techniques such as linear threading or fanning.
This allows a relatively broad area to be approached through a limited number of skin entry sites, which can be a meaningful advantage for certain localized treatments.
Needle-based multipuncture delivery works differently. Individual locations can be directly accessed and small deposits can be placed point by point.
One useful analogy is that cannula treatment can resemble filling an area with multiple lines, whereas multipuncture injection resembles placing dots at predefined locations.
Reach is not the same as distribution
A cannula being physically able to reach a location does not by itself demonstrate that the entire surrounding skin has received product at a uniform depth, spacing, or concentration.
For diffuse full-face skin-quality treatment, I therefore distinguish between reachability and spatial distribution.
When the treatment goal is to create many small deposits throughout broad areas of skin, a point-by-point approach can be conceptually straightforward. When the goal is to treat a defined region along a specific plane, a cannula may be efficient.
Why facial anatomy matters
The face is not a flat surface. The forehead, temple, infraorbital area, cheek, nasolabial region, perioral area, and chin differ in curvature, skin thickness, subcutaneous tissue, vascular anatomy, retaining structures, and underlying muscles.
For that reason, a small number of entry points cannot automatically be assumed to provide equivalent distribution throughout every facial region.
A skilled injector can certainly create dense coverage with a cannula by increasing the number of entry sites and performing multiple passes. However, doing so changes the balance between one of the cannula's major advantages—limited skin punctures—and the desire for increasingly dense spatial coverage.
What does the skin-booster literature say about automated injection?
A 2024 review in Archives of Plastic Surgery discussed several methods of intradermal skin-booster delivery. The authors described automatic multineedle injectors as devices developed to improve the accuracy and stability of intradermal injections.
This does not establish that automated injection is superior for every skin booster. It does show that repeated controlled intradermal microinjection is a recognized delivery strategy in the skin-booster literature.
The most relevant evidence: the 2026 Re2O clinical study
In the 2026 clinical study evaluating injectable particulate human acellular dermal matrix corresponding to Re2O, the investigators used an automated Dermashine injection device to ensure consistent injection depth and dosing accuracy, targeting the mid-dermis.
For clinicians trying to align treatment with the conditions under which a product was actually studied, this is directly relevant information.
It is one reason I consider Dermashine-based mid-dermal injection a reasonable evidence-aligned starting point for diffuse full-face Re2O treatment.
What the study does not prove
The Re2O study did not contain a cannula comparison arm.
Therefore, it cannot establish that Dermashine provides better clinical outcomes than cannula delivery. It also does not establish that cannula treatment is inappropriate.
Likewise, current Re2O-specific evidence does not demonstrate that Re2O must be administered by cannula.
The accurate conclusion is narrower: the published Re2O clinical protocol used automated Dermashine injection targeting the mid-dermis.
What about bruising, redness, and pain?
A randomized split-face study published in 2023 compared cannula and needle delivery of a resilient hyaluronic-acid filler in the nasolabial folds. Some local treatment reactions—including bruising, redness, and pain—occurred less frequently on the cannula-treated side.
That finding is useful, but its limits are important. The study evaluated an HA filler in the nasolabial folds, not Re2O delivered as a full-face skin booster.
It should therefore be regarded as indirect evidence about injection-tool tolerability rather than direct evidence for Re2O technique selection.
Can repeated cannula passes cause more post-inflammatory pigmentation?
Inflammation and mechanical trauma can contribute to post-inflammatory hyperpigmentation, particularly in individuals who are prone to pigmentary change.
However, available evidence does not establish that repeated cannula passes during Re2O treatment cause more PIH than needle multipuncture injection.
Needle treatment also involves mechanical penetration. A direct Re2O-specific head-to-head comparison is lacking. Evidence remains limited.
How I select the delivery method
For texture, fine lines, elasticity, and broad skin-quality goals, I generally consider automated multineedle or manual point-by-point injection.
For selected areas such as the nasolabial region, malar area, or other clearly defined targets, cannula delivery may be appropriate depending on anatomy and the desired tissue plane.
Technique comparison
Useful for repeated delivery under predefined settings across broader treatment areas. Settings still require adjustment to anatomy and skin characteristics.
Allows highly localized adjustment of depth, position, and deposited volume. Operator technique plays a major role.
Can cover selected regions from relatively few entry sites and is useful when linear or fanning distribution within a target plane is desired.
Who may be suitable?
Suitability cannot be determined solely from the name of a product or injection device. Facial anatomy, skin thickness, previous procedures, treatment goals, medical history, and the intended tissue plane should all be reviewed.
For patients seeking broad skin-quality treatment, point-by-point delivery may align well with the intended distribution. For a localized structural target, a cannula may offer practical advantages. This cannot be determined without an in-person assessment.
Questions worth asking before treatment
☐ Is the goal full-face skin quality or a localized target?
☐ Why was this particular delivery tool selected?
☐ What tissue layer is being targeted?
☐ What evidence supports the proposed technique?
☐ Are direct Re2O data being distinguished from indirect filler data?
☐ What bruising, swelling, pain, or other reactions may occur?
☐ What is the follow-up plan if an unexpected reaction develops?
FAQ
No. Current Re2O-specific clinical evidence does not establish cannula delivery as mandatory. The published 2026 clinical study used Dermashine automated injection targeting the mid-dermis.
No direct superiority study has been published in the evidence discussed here. The clinical trial did not contain a cannula arm, so a head-to-head conclusion cannot be made.
It can repeatedly deliver product at multiple locations under predefined settings, which may be useful when broad point-by-point intradermal distribution is intended.
Not necessarily. Manual injection allows the physician to adjust depth, location, and deposited volume in real time. The optimal approach depends on the anatomical area and treatment objective.
It can be used to access broad areas, depending on technique. Achieving dense point-by-point-like distribution may require additional entry sites and multiple tracts.
No universal conclusion can be made. Some filler studies reported less bruising and other local reactions with cannula delivery, but those findings cannot automatically be transferred to full-face Re2O treatment.
The 2026 Re2O study targeted the mid-dermis. Clinical anatomy varies across facial regions and patients, so actual treatment planning requires individual assessment.
This has not been established in a Re2O-specific head-to-head study. Mechanical trauma and inflammation can contribute to PIH, but comparative risk between these delivery methods remains uncertain.
A cannula can approach a defined target plane from a limited number of entry sites and distribute product along linear or fanning paths, which can be efficient for selected anatomical targets.
The rationale behind the technique: the treatment target, anatomy, intended tissue plane, dose distribution, safety considerations, evidence, and the clinician's ability to explain alternatives and limitations.
The practical conclusion
The current evidence supports a more nuanced answer than “cannula is better” or “needle is better.”
The 2026 Re2O clinical study provides direct evidence that the product was clinically evaluated using Dermashine automated injection targeting the mid-dermis. It does not establish superiority over cannula injection.
For diffuse full-face treatment, I generally favor a point-by-point distribution strategy using automated or manual needle injection. For selected localized targets, a cannula may be useful when anatomy and the intended plane support that approach.
Results may vary, and technique selection should be individualized rather than determined solely by the name of an injection device.
References
- Lee YI, Chau NH, Nguyen NH, et al. Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration: An Integrated Randomized, Split-Face, Double-Blinded Clinical Trial and Preclinical Study. International Journal of Molecular Sciences. 2026;27(5):2193. doi:10.3390/ijms27052193.
- Rho NK, Kim HS, Kim SY, Lee W. Injectable “Skin Boosters” in Aging Skin Rejuvenation: A Current Overview. Archives of Plastic Surgery. 2024;51(6):528-541. doi:10.1055/a-2366-3436.
- Beer K, Biesman B, Cox SE, Smith S, Picault L, Trevidic P. Efficacy and Safety of Resilient Hyaluronic Acid Fillers Injected with a Cannula: A Randomized, Evaluator-Blinded, Split-Face Controlled Study. Clinical, Cosmetic and Investigational Dermatology. 2023;16:959-972. doi:10.2147/CCID.S402315.
- Mar K, Khalid B, Maazi M, et al. Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review. Journal of Cutaneous Medicine and Surgery. 2024;28(5):473-480. doi:10.1177/12034754241265716.
At Springday Clinic Sinchon, treatment planning begins with facial anatomy, skin condition, previous procedures, and whether the goal is diffuse skin-quality improvement or a localized target. The available delivery options, limitations, and expected reactions should be discussed before treatment.